Compare AbbVie Inc (ABBV) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Roblox Corp — how do they compare? AbbVie Inc trades at $247.48 (market cap $441.94B), while Roblox Corp trades at $35.59 (market cap $25.87B). The key difference: AbbVie Inc is far larger — about 17.1× Roblox Corp's market cap, and AbbVie Inc pays a 2.77% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| ABBV | RBLX | |
|---|---|---|
Market Cap | $441.94B | $25.87B |
Sector | Health | Media |
52-Week High | $263.58 | $141.56 |
52-Week Low | $197.38 | $35.60 |
Enterprise Value | $506.19B | $24.70B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Roblox (RBLX) trades at $35.33, down 4.64% on the day, amid a bearish technical signal and negative investor sentiment driven by multiple class-action lawsuits. The company shows strong revenue growth, with 2025 revenue reaching $4.89 billion, but remains unprofitable with a net income margin of -17.61%. Recent earnings have beaten expectations, yet management withdrew full-year 2026 guidance, increasing uncertainty.
The outlook is mixed: robust user engagement and revenue growth offer long-term potential, but near-term risks from legal challenges and persistent losses warrant caution. Analyst consensus is a Buy with a $45.67 price target, suggesting upside if execution improves, though volatility from negative news flow may pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
